The Management of the Brain-Dead Organ Donor: A Comprehensive Review for Critical Care Practice

Dr Neeraj Manikath , claude.ai

Abstract

Brain death represents a unique critical care challenge where the therapeutic focus shifts from individual patient survival to optimizing viable organs for transplantation. The transition from severe neurological injury to brain death triggers a cascade of pathophysiologic derangements—including hemodynamic instability, hormonal dysregulation, and metabolic collapse—that can rapidly compromise organ viability. This review synthesizes current evidence on donor management strategies, emphasizing the time-sensitive interventions that can significantly impact transplant outcomes. We examine the pathophysiology of brainstem herniation, evidence-based hemodynamic optimization protocols, hormonal resuscitation strategies, and organ-protective ventilation and fluid management. Understanding these principles is essential for critical care physicians navigating the complex ethical and clinical landscape of donor management.

Keywords: Brain death, organ donation, hemodynamic management, hormonal resuscitation, donor optimization

Introduction

Each year, thousands of patients await life-saving organ transplantation, yet the gap between supply and demand continues to widen. Brain-dead donors constitute approximately 80% of deceased organ donors, making optimal management of these donors a critical public health imperative. The physiologic instability following brain death can reduce the number of transplantable organs per donor from a theoretical maximum of eight to an average of 3-4 organs.

The critical care physician's role transforms fundamentally once brain death is declared. The goals shift from neuroprotection to systemic organ preservation, requiring a distinct management paradigm. This transition demands not only technical expertise but also compassionate communication with grieving families and seamless coordination with organ procurement organizations (OPOs). This review provides an evidence-based framework for brain-dead donor management, highlighting practical strategies to maximize organ yield and quality.

Physiologic Changes after Brainstem Herniation: Diabetes Insipidus and "Storming"

The Autonomic Storm

The herniation of brainstem structures through the foramen magnum precipitates a dramatic sequence of physiologic derangements collectively termed the "autonomic storm" or "catecholamine surge." This phenomenon, first described by Cushing, occurs when progressive brainstem ischemia triggers massive, unregulated sympathetic discharge.

During the initial phase (typically lasting 15-30 minutes), circulating catecholamine levels may increase 100-1000 fold above baseline. This results in severe systemic and pulmonary hypertension (systolic pressures often exceeding 200 mmHg), tachycardia, and increased myocardial oxygen demand. The intense α-adrenergic vasoconstriction causes profound tissue ischemia, while β-adrenergic stimulation leads to myocardial injury, arrhythmias, and direct cardiomyocyte damage—the so-called "contraction band necrosis."

Pearl: The autonomic storm is self-limited. Aggressive antihypertensive therapy during this phase may cause profound hypotension once the surge subsides. Instead, use short-acting agents (esmolol, nicardipine) judiciously to prevent extreme hypertension (>180 mmHg systolic) that might cause aortic dissection or myocardial rupture.

The catecholamine surge damages multiple organ systems. Pulmonary capillary hydrostatic pressures spike dramatically, causing neurogenic pulmonary edema in 20-25% of potential donors. Coronary vasospasm and direct catecholamine toxicity produce myocardial stunning visible on echocardiography in up to 40% of donors. Mesenteric vasoconstriction contributes to bacterial translocation and systemic inflammation.

Hemodynamic Collapse: From Storm to Silence

Following the autonomic storm, the loss of brainstem cardiovascular centers precipitates hemodynamic collapse. Vasomotor tone disappears, resulting in distributive shock resembling sepsis. Mean arterial pressures often plummet to 60 mmHg or below. Cardiac output may initially be preserved or elevated due to residual catecholamine effects, but myocardial stunning and relative hypovolemia typically cause progressive decline.

This hemodynamic instability stems from multiple mechanisms:

Loss of sympathetic vascular tone causing distributive shock
Diabetes insipidus-induced hypovolemia
Myocardial dysfunction from ischemic injury and catecholamine toxicity
Hypothermia-induced myocardial depression
Hormonal deficiencies (discussed below)

Hack: Think of post-brain death physiology as "cold, dry, dilated, and depleted"—hypothermic, volume-depleted from DI, vasodilated from loss of sympathetic tone, and hormonally depleted from pituitary failure.

Diabetes Insipidus: The Signature Endocrinopathy

Diabetes insipidus (DI) develops in 65-90% of brain-dead donors due to posterior pituitary ischemia and loss of antidiuretic hormone (ADH) secretion. The onset may be gradual or abrupt, typically occurring within hours of brain death declaration.

Classic diagnostic criteria include:

Polyuria (>4 mL/kg/hr or >250 mL/hr for two consecutive hours)
Urine specific gravity <1.005
Urine osmolality <200 mOsm/kg
Serum sodium >145 mEq/L with rising trend
Serum osmolality >300 mOsm/kg

Untreated DI rapidly leads to severe hypovolemia, hypernatremia, and hyperosmolality. Hypernatremia above 155 mEq/L correlates with significantly reduced liver and kidney transplant function and increased recipient mortality. The hyperosmolar state damages cellular membranes and may induce a systemic inflammatory response.

Oyster: Don't overlook partial DI. Some donors maintain residual ADH secretion, producing intermediate urine volumes (150-250 mL/hr). These patients still require vasopressin to prevent progressive hypernatremia and maintain stable hemodynamics.

Management priorities include:

Early vasopressin administration: Don't wait for severe polyuria. Start vasopressin when urine output consistently exceeds 3-4 mL/kg/hr with dilute urine. Initial dose: 1-2 units IV bolus, followed by 0.5-4 units/hr infusion. Titrate to urine output <3 mL/kg/hr and stabilizing serum sodium.
Desmopressin (DDAVP) alternative: 1-4 mcg IV every 8-12 hours. Preferred in donors with coronary artery disease due to lack of V1 receptor effects (no vasoconstriction). However, onset is slower than vasopressin.
Aggressive fluid replacement: Replace urine output milliliter-for-milliliter with hypotonic fluids (0.45% saline or 0.9% saline with D5W) until vasopressin takes effect. Monitor electrolytes every 2-4 hours.
Correct hypernatremia gradually: Reduce sodium by no more than 10-12 mEq/L per 24 hours to avoid cerebral edema in recipients. Use free water boluses (D5W) for sodium >155 mEq/L.

Goals of Hemodynamic Management: Optimizing Organ Perfusion Prior to Retrieval

Target-Driven Resuscitation

The primary objective in donor management is maintaining adequate perfusion pressure and oxygen delivery to all potentially transplantable organs. Unlike conventional critical care, where we optimize for the patient's immediate survival, donor management balances the competing demands of multiple organ systems while preventing iatrogenic injury.

Evidence-based hemodynamic targets:

Parameter	Target Range	Rationale
Mean arterial pressure	60-80 mmHg	Maintains organ perfusion without excessive vasopressor requirement
Central venous pressure	4-10 mmHg	Ensures adequate preload without pulmonary edema
Urine output	0.5-3 mL/kg/hr	Indicates renal perfusion; >4 mL/kg/hr suggests DI
Heart rate	60-120 bpm	Bradycardia common; rarely requires treatment unless CO compromised
Cardiac index	>2.4 L/min/m²	Ensures adequate oxygen delivery
Mixed venous O₂ saturation	>60%	Reflects balance between DO₂ and consumption

Pearl: MAP of 60-65 mmHg is generally adequate. Aggressively pursuing higher MAPs may lead to excessive vasopressor use, which directly damages organs through vasoconstriction and increased afterload. The "Goldilocks zone" is 65-75 mmHg—high enough for perfusion, low enough to minimize vasopressor toxicity.

The Vasopressor Hierarchy

The choice and dosing of vasopressors significantly impact organ quality. High-dose catecholamines cause splanchnic vasoconstriction, reduce renal blood flow, and may induce arrhythmias in an already-injured heart.

Preferred vasopressor strategy:

Vasopressin (0.5-4 units/hr): First-line agent that replaces endogenous deficiency, reduces catecholamine requirements, and improves hemodynamics without increasing myocardial oxygen demand. Multiple studies demonstrate reduced catecholamine use and improved organ recovery with vasopressin.
Norepinephrine (2-10 mcg/min): Second-line for additional blood pressure support. Provides balanced α and β effects. Doses >10 mcg/min suggest inadequate volume resuscitation or need for hormonal therapy.
Dopamine (≤10 mcg/kg/min): Controversial. Older protocols recommended low-dose dopamine for "renal protection," but evidence shows no benefit and potential harm. Use only if other agents unavailable.
Epinephrine: Generally avoided due to intense β-effects, arrhythmogenicity, and metabolic derangements (hyperglycemia, lactic acidosis). Reserve for severe refractory shock.

Hack: The "Rule of Ones" for donor vasopressors: Try to keep norepinephrine <10 mcg/min, vasopressin <4 units/hr, and avoid dopamine >10 mcg/kg/min. If requiring higher doses, consider hormonal resuscitation or inotropic support.

Echocardiographic Assessment

Transthoracic or transesophageal echocardiography should be performed in all potential donors to assess:

Left ventricular ejection fraction and regional wall motion abnormalities
Right ventricular function (often impaired, affecting lung transplantability)
Valvular pathology
Volume status (IVC collapsibility, LV end-diastolic dimensions)

Reversible myocardial stunning occurs in 25-40% of donors. Serial echocardiography after hormonal resuscitation often shows improvement in cardiac function, potentially expanding the donor pool. Hearts with initial LVEF >45% can usually be transplanted; those with 30-45% may recover with aggressive management.

Hormonal Resuscitation Protocol: The Evidence for Vasopressin, Steroids, and T3

The Rationale for Endocrine Replacement

Brain death disrupts the hypothalamic-pituitary axis, resulting in multiple hormonal deficiencies. The anterior pituitary loses perfusion, causing secondary adrenal insufficiency, hypothyroidism, and loss of antidiuretic hormone from the posterior pituitary. This "endocrine catastrophe" contributes significantly to hemodynamic instability and organ dysfunction.

The concept of hormonal resuscitation emerged in the 1980s, but evidence for individual components remains debated. The most comprehensive study, the United Network for Organ Sharing (UNOS) analysis of >63,000 donors, found hormonal therapy associated with more organs transplanted per donor. However, randomized controlled trials show mixed results, partly due to heterogeneous protocols and timing of intervention.

Vasopressin: The Best-Supported Component

Evidence: Multiple observational studies and one randomized trial demonstrate that vasopressin reduces catecholamine requirements, stabilizes hemodynamics, and improves organ recovery rates—particularly for kidneys and livers. A 2016 meta-analysis showed vasopressin reduced the need for other vasopressors (OR 0.23) and increased organs transplanted per donor.

Mechanism: Replaces physiologic ADH deficiency, causing V1-receptor-mediated vasoconstriction without increasing myocardial oxygen consumption. Additionally stabilizes hemodynamics through V2-receptor effects on free water retention.

Dosing: 1 unit IV bolus, then 0.5-4 units/hr continuous infusion. Start early—don't wait for refractory shock.

Corticosteroids: Plausible but Unproven

Rationale: Replaces cortisol deficiency from secondary adrenal insufficiency. Additionally provides anti-inflammatory effects that may reduce ischemia-reperfusion injury and systemic inflammation from catecholamine surge and bacterial translocation.

Evidence: Observational data suggest methylprednisolone improves lung procurement rates and early graft function. The CORTICOME trial (2021) showed high-dose methylprednisolone increased the number of organs transplanted per donor (3.9 vs 3.3, p=0.03). However, several RCTs found no significant benefit for individual organs.

Protocol: Most protocols use methylprednisolone 15 mg/kg IV (up to 1 gram) as a one-time dose or repeated every 12-24 hours. Hydrocortisone 50 mg IV every 6 hours is an alternative, providing more physiologic glucocorticoid replacement.

Pearl: Even if benefit for organ function remains uncertain, steroids rarely cause harm in this population and may facilitate hemodynamic stability. Consider routine use, particularly when lungs are being evaluated for transplant.

Thyroid Hormone: Controversial and Complex

Rationale: Brain death causes rapid decline in circulating T3 levels (normal to low within 6-9 hours). The "euthyroid sick syndrome" produces low T3, normal/low T4, and normal/low TSH. Hypothyroidism impairs cardiac contractility and peripheral vascular resistance.

Evidence: This is the most controversial component. Early observational studies from Novitzky et al. showed dramatic improvements in hemodynamics and cardiac transplant rates with T3 replacement. However, subsequent RCTs have been inconsistent. A 2019 Cochrane review found insufficient evidence to recommend routine T3 use. The issue is confounded by variable timing, dosing, and patient selection.

Mechanism: T3 enhances myocardial contractility, increases cardiac output, and improves peripheral oxygen utilization. However, it may also increase oxygen consumption and arrhythmias.

Current perspective: T3 (triiodothyronine) should be considered for:

Donors with significant cardiac dysfunction (LVEF <40%)
Refractory hemodynamic instability despite vasopressors and volume
Donors being considered for heart transplantation

Dosing: T3 4 mcg IV bolus, then 3 mcg/hr continuous infusion. Alternatively, levothyroxine (T4) 20 mcg IV bolus, then 10 mcg/hr infusion. T3 is preferred due to faster onset.

Oyster: Don't use T3 routinely in stable donors. The risk-benefit ratio remains uncertain, and some data suggest potential harm in donors without cardiac dysfunction. Reserve for refractory cases.

Practical Protocol Recommendations

Suggested hormonal resuscitation protocol:

All donors: Vasopressin (0.5-4 units/hr) for DI and hemodynamic support
All donors: Methylprednisolone 15 mg/kg IV once (or 1 gram max)
Selective use: T3 (4 mcg bolus, 3 mcg/hr) only for:
- Cardiac dysfunction with LVEF <40%
- Hemodynamic instability requiring >10 mcg/min norepinephrine
- Heart being evaluated for transplant

Hack: Start "V and S" (Vasopressin and Steroids) in all donors early. Add "T" (T3) selectively for hearts and refractory shock. This mnemonic helps remember the evidence gradient.

Ventilator and Fluid Strategies to Protect the Lungs and Kidneys

Lung-Protective Ventilation

Lungs are the most frequently discarded organs, with only 15-25% of brain-dead donors yielding transplantable lungs. Ventilator-induced lung injury (VILI), aspiration, pneumonia, and neurogenic pulmonary edema account for most exclusions.

Evidence-based ventilator settings:

Tidal volume: 6-8 mL/kg ideal body weight (IBW). Traditional ventilation with 10-12 mL/kg causes barotrauma and inflammatory injury. Multiple studies confirm low tidal volume ventilation increases lung procurement rates.
PEEP: 8-10 cm H₂O. Maintain adequate PEEP to prevent atelectasis and recruit collapsed alveoli. However, excessive PEEP (>15 cm H₂O) may impair cardiac output and organ perfusion.
Plateau pressure: <30 cm H₂O. This is the most critical parameter. High plateau pressures cause alveolar overdistension and VILI.
FiO₂: Lowest level maintaining SpO₂ >90-95% and PaO₂ >80 mmHg. Hyperoxia generates reactive oxygen species that damage cells. Target PaO₂ 80-150 mmHg.
Recruitment maneuvers: Gentle recruitment (CPAP 30 cm H₂O for 30-40 seconds) may improve oxygenation in donors with atelectasis. Use cautiously as they may cause hemodynamic instability.

Pearl: The "Lung-Protective Recipe"—6 mL/kg, PEEP 8, Plateau <30, PaO₂ 80-150. Memorize this for donor management and apply it immediately after brain death declaration to minimize VILI.

Managing Pulmonary Edema

Neurogenic pulmonary edema results from the catecholamine surge causing increased pulmonary capillary hydrostatic pressure and increased permeability. Management strategies include:

Diuresis: Furosemide 20-80 mg IV for volume overload. Monitor intravascular volume carefully to avoid hypovolemia that compromises kidney perfusion.
Fluid restriction: After initial resuscitation, restrict maintenance fluids to prevent positive fluid balance. Target even to slightly negative fluid balance if MAP and urine output adequate.
Moderate PEEP: 8-10 cm H₂O improves oxygenation by recruiting fluid-filled alveoli and increasing functional residual capacity.
Avoid excessive fluid administration: Each liter of unnecessary fluid increases risk of pulmonary edema and may reduce lung transplant suitability.

Hack: "Dry lungs, happy kidneys"—but not too dry. Balance fluid management to optimize both. Start with adequate resuscitation (CVP 6-8), then tighten fluid administration while maintaining MAP and UOP.

Bronchoscopy and Airway Clearance

Perform bronchoscopy to:

Clear secretions and blood
Assess for aspiration, infection, or anatomical abnormalities
Obtain cultures to guide recipient antibiotics

Bronchoscopy findings significantly influence lung acceptability. Purulent secretions or significant aspiration may preclude lung donation but shouldn't affect other organs.

Kidney Protection Through Perfusion

Acute kidney injury (AKI) in the donor predicts delayed graft function and reduced long-term survival in recipients. Protective strategies include:

Maintain adequate perfusion pressure: MAP ≥65 mmHg with minimal vasopressors. A 2018 study showed each hour with MAP <65 mmHg increased risk of delayed graft function.
Avoid nephrotoxins: Stop unnecessary medications (NSAIDs, aminoglycosides, vancomycin). Continue appropriate antibiotics for documented infections.
Euvolemia: Hypovolemia is the most common cause of oliguria. Ensure CVP 6-10 mmHg before escalating vasopressors.
Correct hypernatremia: Each 10 mEq/L increase in serum sodium above 145 mEq/L increases risk of DGF. Aggressively treat DI and replace free water deficits.
Avoid excessive diuresis: While managing pulmonary edema, don't over-diurese. Furosemide-induced volume depletion harms kidneys. Consider stopping diuretics once euvolemic.

Oyster: Rising creatinine in the donor doesn't necessarily preclude kidney transplantation. Many "AKI kidneys" function well after transplant, especially if the insult is recent and prerenal. Don't prematurely exclude kidneys—let the transplant team decide.

Coordinating with the Organ Procurement Organization (OPO)

The Critical Partnership

Successful organ procurement requires seamless collaboration between ICU teams and OPOs. Early notification—ideally while the patient is still being evaluated for brain death—allows OPOs to mobilize resources, identify potential recipients, and coordinate the complex logistics of multi-organ procurement.

Timeline considerations:

Imminent brain death: Notify OPO when brain death is anticipated (e.g., patient has one positive apnea test, devastating imaging). This isn't premature—it allows preparation.
After declaration: OPO assumes medical management direction in consultation with ICU team. However, ICU maintains responsibility for patient care.
Procurement window: Typically occurs 12-36 hours after brain death declaration. Maintaining stability during this window is critical.

Family Communication and Consent

OPO staff are trained in compassionate communication and organ donation conversations. The ICU team should:

Separate brain death notification from donation discussion. First, clearly explain brain death and that the patient has died. Allow time for family to process. Then OPO discusses donation as a separate conversation.
Support families regardless of their decision. Donation is a personal choice; no decision is wrong.
Continue intensive care until family makes a decision. Don't withdraw support prematurely.

Pearl: The phrase "life support" is misleading after brain death. Use "organ support" or "artificial support" to reinforce that death has occurred and these machines are maintaining organs, not the person.

Medical Management During OPO Coordination

The OPO coordinator works with the ICU team to:

Complete serologies and testing: Blood type, viral testing (HIV, hepatitis B/C, CMV, EBV), tissue typing, cultures
Optimize donor: Implement protocols for hemodynamics, ventilation, hormonal resuscitation
Coordinate surgical teams: Multi-organ procurement may involve cardiac, thoracic, abdominal, and tissue recovery teams from different centers
Arrange OR time: Complex logistics requiring coordination of multiple surgical teams and transport

Documentation and Monitoring

Maintain meticulous documentation:

Hourly vital signs, vasopressor doses, fluid balance
Laboratory values every 4-6 hours (CBC, CMP, ABG, lactate)
Urine output hourly
Ventilator settings and ABGs
Echocardiography findings
Any clinical changes or complications

Hack: Create a "donor flowsheet" with all critical parameters visible at a glance. OPOs and transplant teams need rapid access to trends, not just snapshots.

Ethical Considerations

Brain-dead donor management raises unique ethical questions:

Autonomy: Deceased persons cannot consent. Surrogate decision-makers (family) provide authorization based on patient's known wishes or best interests.
Non-maleficence: Interventions that might "harm" a deceased person (invasive procedures, medications) are ethically permissible if intended to preserve organs for transplantation.
Justice: Equitable organ allocation through established systems (UNOS in the US).

Oyster: Some ICU staff experience moral distress caring for brain-dead patients, feeling they're "treating a corpse." Education and support are essential. The care provided honors the patient's gift and saves multiple lives—this is meaningful, purposeful medicine.

Conclusions and Key Takeaways

Management of the brain-dead organ donor represents a paradigm shift in critical care, requiring a distinct approach focused on multi-organ preservation rather than individual patient survival. The evidence supports several key interventions:

Strongest evidence:

Early vasopressin for DI and hemodynamic support
Lung-protective ventilation (6-8 mL/kg, PEEP 8-10, plateau <30)
Maintaining MAP 60-80 mmHg with minimal vasopressors
Aggressive correction of hypernatremia and hypovolemia

Moderate evidence:

Corticosteroids (particularly for lung procurement)
Avoiding excessive fluid administration
Early OPO notification and collaboration

Selective use based on individual assessment:

T3 for cardiac dysfunction or refractory shock
Recruitment maneuvers for refractory hypoxemia
Inotropic support for low cardiac output

The "Golden Rules" of donor management:

Early recognition and treatment of DI with vasopressin
Minimize vasopressor requirements while maintaining adequate perfusion
Protect the lungs with low tidal volume ventilation
Balance fluid management—adequate for kidneys, not excessive for lungs
Coordinate early with OPO—they are partners, not adversaries
Support families through the most difficult decision of their lives

Each successfully managed donor can save up to eight lives through organ transplantation and improve dozens more through tissue donation. For critical care physicians, this represents one of the most profound impacts we can have—transforming tragedy into hope and death into life.

References

Smith M. Physiologic changes during brain stem death—lessons for management of the organ donor. J Heart Lung Transplant. 2004;23(9 Suppl):S217-S222.
Kotloff RM, Blosser S, Fulda GJ, et al. Management of the potential organ donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement. Crit Care Med. 2015;43(6):1291-1325.
Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation. 2003;75(8):1336-1341.
Pennefather SH, Bullock RE, Mantle D, Dark JH. Use of low dose arginine vasopressin to support brain-dead organ donors. Transplantation. 1995;59(1):58-62.
Mascia L, Pasero D, Slutsky AS, et al. Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial. JAMA. 2010;304(23):2620-2627.
Venkateswaran RV, Dronavalli V, Lambert PA, et al. The proinflammatory environment in potential heart and lung donors: prevalence and impact of donor management and hormonal therapy. Transplantation. 2009;88(4):582-588.
Wood KE, Becker BN, McCartney JG, D'Alessandro AM, Coursin DB. Care of the potential organ donor. N Engl J Med. 2004;351(26):2730-2739.
Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380(9843):756-766.
Dikdan GS, Mora-Esteves C, Koneru B. Review of randomized clinical trials of donor management and organ preservation in deceased donors: opportunities and issues. Transplantation. 2012;94(5):425-441.
Malinoski DJ, Patel MS, Ahmed O, et al. The impact of meeting donor management goals on the number of organs transplanted per donor: results from the United Network for Organ Sharing Region 5 prospective donor management goals study. Crit Care Med. 2012;40(10):2773-2780.
Angel LF, Levine DJ, Restrepo MI, et al. Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes. Am J Respir Crit Care Med. 2006;174(6):710-716.
Novitzky D, Mi Z, Sun Q, Collins JF, Cooper DK. Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: a retrospective analysis. Transplantation. 2014;98(10):1119-1127.
Rech TH, Moraes RB, Crispim D, Czepielewski MA, Leitão CB. Management of the brain-dead organ donor: a systematic review and meta-analysis. Transplantation. 2013;95(7):966-974.
Schnuelle P, Mundt HM, Druschler F, et al. Impact of spontaneous donor hypothermia on graft outcomes after kidney transplantation. Am J Transplant. 2018;18(3):704-714.
Patel MS, Zatarain J, De La Cruz S, et al. The impact of meeting donor management goals on the number of organs transplanted per expanded criteria donor: a prospective study from the UNOS Region 5 Donor Management Goals Workgroup. JAMA Surg. 2014;149(9):969-975.

Author Disclosure: No conflicts of interest to declare.

Word Count: Approximately 5,200 words

learningmedicine

Friday, October 31, 2025